Novo vs. KBP: How a $1.3B deal turned into an international legal fight
accelerated
Biotech

Regeneron, Sanofi receive 1- to 2-month priority review vouchers

The national priority vouchers position companies including Merck KGaA, Regeneron and Sanofi to complete the review process in one to two months.
Nick Paul Taylor Oct 17, 2025 8:30am
ESMO AstraZeneca

ESMO: AstraZeneca data ‘validate’ focus on in-house ADCs

Oct 18, 2025 12:55pm
ESMO Berlin 2025

ESMO: Roche wants oral SERD to benefit ‘all comers’

Oct 18, 2025 1:00am
Heat red cracked ground texture burning after volcano eruption Molten active lava texture background

Xoma and Lava buyout cools with lower offer

Oct 17, 2025 2:35pm
vials vaccine research vaccines factory manufacturing

Evaxion stock slips on phase 2 cancer vax data

Oct 17, 2025 2:07pm
weight loss from cancer

ESMO: Pfizer sees year-long weight gain in cancer patients

Oct 17, 2025 12:45pm
More News

Hansoh, Chugai ink separate and lucrative licensing agreements

Oct 17, 2025 11:04am

Astellas turns down option to license Taysha gene therapy—again

Oct 17, 2025 10:50am

I-Mab unveils new name, strategy, asset and Hong Kong IPO plans

Oct 17, 2025 10:45am

ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals

Oct 17, 2025 10:30am